Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
1(7%)
Results Posted
36%(5 trials)

Phase Distribution

Ph phase_3
4
27%
Ph phase_2
1
7%
Ph phase_1
10
67%

Phase Distribution

10

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
10(66.7%)
Phase 2Efficacy & side effects
1(6.7%)
Phase 3Large-scale testing
4(26.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(14)

Detailed Status

Completed14
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (66.7%)
Phase 21 (6.7%)
Phase 34 (26.7%)

Trials by Status

active_not_recruiting17%
completed1493%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT05587296Phase 3

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Active Not Recruiting
NCT05099159Phase 3

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Completed
NCT05042362Phase 3

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

Completed
NCT05030584Phase 3

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

Completed
NCT05071729Phase 1

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Completed
NCT06219902Phase 1

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

Completed
NCT04889287Phase 1

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

Completed
NCT05481528Phase 1

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Completed
NCT03596762Phase 2

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Completed
NCT05471817Phase 1

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Completed
NCT05381142Phase 1

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

Completed
NCT05351892Phase 1

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

Completed
NCT04981431Phase 1

A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults

Completed
NCT05061563Phase 1

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

Completed
NCT05028608Phase 1

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15